Previous 10 | Next 10 |
home / stock / wllw:cc / wllw:cc news
--News Direct-- Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to announce some significant developments within the company. Willow Bioscience specializes in the production of ursodeoxycholic acid (UDCA), a vital pharmaceutical ingredient with extensive appl...
WILLOW BIOSCIENCES ANNOUNCES COMPANY INSIDER LED CONVERTIBLE DEBENTURE FINANCING Canada NewsWire /NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES . ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITI...
WILLOW ANNOUNCES SUCCESSFUL COMPLETION OF R&D PROGRAM ON COST-EFFECTIVE, SUSTAINABLY PRODUCED UDCA WILLOW ANNOUNCES SUCCESSFUL COMPLETION OF R&D PROGRAM ON COST-EFFECTIVE, SUSTAINABLY PRODUCED UDCA Canada NewsWire Company's BioOxi™ Platform solves for select...
--News Direct-- Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to announce a groundbreaking development in the pharmaceutical industry. Savile shared the company's achievement in creating a cost-effective process for producing corticosteroids using their inn...
WILLOW ANNOUNCES FILING OF PATENT APPLICATION FOR PROCESS TO PRODUCE CORTICOSTEROIDS AT SIGNFICANTLY REDUCED COST Canada NewsWire Company's BioOxi™-based process reduces number of steps and associated costs of corticosteroids manufacturing by up to two-thirds ...
--News Direct-- Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to share news the company has embarked on a major strategic shift, focusing its commercial efforts on the BioOxi platform. To assist in this transition, Willow Biosciences has engaged an advisor to e...
WILLOW BIOSCIENCES ANNOUNCES COMMERCIAL TRANSITION AND FOCUS ON BIOOXI PLATFORM Canada NewsWire Announces commercial focus on BioOxi TM bio-oxidation platform as part of targeted alignment on nearer-term and larger revenue opportunities Reduces number of board memb...
WILLOW ANNOUNCES COLLABORATION WITH A LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS Canada NewsWire SUNNYVALE, Calif. , Aug. 21, 2023 /CNW/ - Willow Biosciences Inc. (" Willow ") (TSX:&...
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Canada NewsWire New partnerships and contracts expected to bring in over $1 million in near-term R&D/milestone revenue and generate long term commercial revenue SUNNYVALE, Calif. , A...
WILLOW AND KALSEC ADVANCE DEVELOPMENT PROGRAM FOR NEW NATURAL FUNCTIONAL INGREDIENT FOR SAVORY FOODS Canada NewsWire Program further validates Willow's technology and focus on commercial execution and aligns with its strategic focus on near term revenue generation KA...
News, Short Squeeze, Breakout and More Instantly...
Willow Biosciences Inc. Company Name:
WLLW:CC Stock Symbol:
TSXC Market:
Willow Biosciences Inc. Website:
WILLOW BIOSCIENCES ANNOUNCES CLOSING OF PRIVATE PLACEMENT OF UNITS Canada NewsWire /NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES ./ CALGARY, AB , July 18, 2024 /CNW/ - Willow Biosciences Inc. ...
WILLOW BIOSCIENCES PROVIDES CORPORATE UPDATE AND ANNOUNCES SIGNING OF A NEW PARTNERED PROGRAM Canada NewsWire Company announced multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical ingredients Company anticipates ...
--News Direct-- Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to share the company's plans to raise approximately $3 million. This capital will be used to support Willow Bioscience's recent partnership announcement with Laurus Labs. Dr. Savile explained tha...